PAVmed (PAVM) majority-owned subsidiary Lucid Diagnostics to spin-off into separate public company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
February 22, 2021 8:18 AM ESTAnnounces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company
Lucid Diagnostics to launch major new multi-channel commercialization initiative for its EsoGuard Esophageal DNA Test
Conference call to be held today at 8:30 AM EST
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Lucid) and Solys Diagnostics Inc. (Solys), discussed preliminary financial results for the... More
